Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Frank-Kamenetsky, Maria; Grefhorst, Aldo; N. Anderson, Norma; Racie, Timothy; Bramlage, Birgit; Akinc, Akin; Butler, David; Charissé, Klaus; Dorkin, Robert; Fan, Yupeng; Gamba‐Vitalo, Christina; Hadwiger, Philipp; Jayaraman, Muthusamy; John, Matthias; N. Jayaprakash, K.; A. Maier, Martin; V. Nechev, Lubomir; G. Rajeev, Kallanthottathil; Read, Timothy; Röhl, Ingo; Soutschek, Jürgen; Tan, Pamela; Wong, Jamie; Wang, Gang; Zimmermann, Tracy; de Fougerolles, Antonin; Vornlocher, Hans-Peter; Langer, Róbert; G. Anderson, Daniel; Manoharan, Muthiah; Koteliansky, Victor; D. Horton, Jay; Fitzgerald, Kevin

doi:10.1073/pnas.0805434105

Public

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Published in Proceedings of the National Academy of Sciences • Aug 11, 2008

Authors:

Maria Frank-Kamenetsky

Aldo Grefhorst

Norma N. Anderson

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma ...

Subject

PCSK9

Kexin

LDL receptor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!